Based on this result, either macrophage-specific ablation of LSECtin or silencing of BTN3A3 in mice bearing human tumor xenografts can block the LSECtin-BTN3A3 axis, decreasing CSC frequency and tumor growth ultimately [146]. The gene discussed is CLEC4G; the disease is neoplasm.